| gap-pubmed-20260410- | What mechanisms determine disease-specific patterns of microglial glucose metabo | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TREK-1 channel mechanosensitivity integrate with glucocorticoid signali | open | 0.77 | 0.00 | 2026-04-10 | 0 | | mechanobiology |
| gap-pubmed-20260410- | What molecular mechanisms link glucocorticoid exposure to TREK-1 transcriptional | open | 0.84 | 0.00 | 2026-04-10 | 0 | | molecular-neurobiology |
| gap-pubmed-20260410- | How do differential changes in mechanosensitive ion channel families translate t | open | 0.73 | 0.00 | 2026-04-10 | 0 | | cellular-neuroscience |
| gap-pubmed-20260410- | What molecular mechanisms drive TNF-α-induced upregulation of TRPA1 and TRPM8 in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms explain CHIP's protective effects in Alzheimer's disease versus | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do specific mutations in TET2, DNMT3A, and ASXL1 alter microglial function i | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms explain why clonal hematopoiesis protects against Alzheimer's di | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does P2RX7 purinergic signaling mechanistically regulate pancreatic β-cell f | open | 0.60 | 0.00 | 2026-04-10 | 0 | | metabolic-signaling |
| gap-pubmed-20260410- | What functional role does the mCH signature play in X-chromosome inactivation es | open | 0.74 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-pubmed-20260410- | How does the widespread methylome reconfiguration during synaptogenesis function | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What mechanisms drive the accumulation of non-CG methylation specifically in neu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which TET2 dysregulation causes in | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does TET2 regulate inflammation independent of its enzymatic DNA demethylati | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do upregulated P2X7 receptors and NLRP3 inflammasomes interact in COVID-19 n | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms link purinergic signaling to coagulation pathways in COVID-19 ne | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does PIKFYVE inhibition rescue diverse ALS forms with different genetic etio | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does PIKFYVE inhibition activate unconventional protein clearance via exocyt | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines cell-type specific regulation of TGM2 alternative splicing in th | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do C-terminal truncated TGM2 splice variants mechanistically contribute to n | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does intracellular serotonin in neuronal nuclei regulate protein function in | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific SERT posttranslational modifications involved in AD pathog | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does serotonylation mechanistically contribute to Alzheimer's disease pathog | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does Tgm2-mediated microglial senescence contribute to specific neurodegenerativ | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of Tgm2 for K22 and Q248 residues on IκBα versus | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does Tgm2-mediated IκBα cross-linking mechanistically differ from canonical | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the specificity of TGM2's dual binding to both SDC1 and LC3 duri | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the SDC1-TGM2-EPG5 autophagy mechanism differ between normal brain cell | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines ALKBH5's substrate specificity for different mRNA targets? | open | 0.74 | 0.00 | 2026-04-10 | 0 | | rna-metabolism |
| gap-pubmed-20260410- | How does ALKBH5-mediated m6A demethylation mechanistically link to spermatocyte | open | 0.77 | 0.00 | 2026-04-10 | 0 | | rna-metabolism |
| gap-pubmed-20260410- | Can targeting stress granule-senescence interplay provide therapeutic interventi | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does senescence switch from anti-tumorigenic to pro-tumorigenic in glioma pr | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link stress granule dynamics to senescence-associated | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether stress granules undergo normal disassembly versus pathol | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is G3BP1 ubiquitination required only for heat shock but not other stress-in | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which PRMT pathways could be synergistically targeted for neurological diseases | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do PRMTs regulate neuronal function and what are the specific mechanisms in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines tissue-specific NAD+ depletion patterns in brain aging versus ot | open | 0.77 | 0.00 | 2026-04-10 | 0 | | aging-neurobiology |
| gap-pubmed-20260410- | How does CX43 mechanistically regulate PARP1 activity in blood-brain barrier end | resolved | 0.84 | 0.00 | 2026-04-10 | 0 | | vascular-neurobiology |
| gap-pubmed-20260410- | How do Hsp70's allosteric mechanisms and substrate interactions specifically reg | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which Hsp70 regulates sleep and co | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do only 11 of 47 diabetes-associated proteins show strong colocalization sup | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link HLA-DRA, AGER, HSPA1A, and HSPA1B to microvascular complica | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do detergent-insoluble protein changes relate temporally to clinical AD prog | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive co-accumulation of non-amyloid/tau proteins in detergent-i | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do newly identified disease-associated proteins functionally contribute to A | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do AD mouse models fail to recapitulate human proteomic changes beyond amylo | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the discrepancies between proteome and transcriptome chang | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do NTN1+ endothelial cells specifically target and communicate with regenera | open | 0.80 | 0.00 | 2026-04-10 | 0 | | peripheral-nerve-regeneration |
| gap-pubmed-20260410- | What molecular mechanisms control let-7a-5p downregulation in NTN1+ endothelial | open | 0.79 | 0.00 | 2026-04-10 | 0 | | peripheral-nerve-regeneration |